1. Home
  2. PCVX

as 06-30-2025 2:32pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Founded: 2013 Country:
United States
United States
Employees: N/A City: SAN CARLOS
Market Cap: 4.4B IPO Year: 2020
Target Price: $136.50 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.98 EPS Growth: N/A
52 Week Low/High: $27.66 - $121.06 Next Earning Date: 08-05-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

PCVX Daily Stock ML Predictions

Share on Social Networks: